glp 1 drugs and anesthesia Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists Glucagon‐like peptide‐1 receptor agonists: a

It plays a key role in glucose and appetite regulation by: Stimulating insulin release (glucose-dependent) Suppressing glucagon secretion Slowing gastric emptying Increasing satiety and reducing appetite In people with type 2 diabetes, this GLP-1 response is impaired leading to poor glycemic control

If you injected less than intended, you may experience reduced effectiveness that week

However, roughly half of the people using these drugs discontinue them within 1 year

Academic researchers have less direct financial stake (though they have career incentives)

Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes

The future of obesity treatment with GLP-1 agonists will likely depend on continued therapeutic innovation and parallel advances in healthcare policy, delivery systems, and equity-focused implementation strategies